USA - NASDAQ:UPC - KYG9442G1385 - Common Stock
Overall UPC gets a fundamental rating of 3 out of 10. We evaluated UPC against 191 industry peers in the Pharmaceuticals industry. The financial health of UPC is average, but there are quite some concerns on its profitability. UPC has a expensive valuation and it also scores bad on growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.35% | ||
| ROE | 1.97% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 5.65% | ||
| GM | 30.41% |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.38 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.78 | ||
| Quick Ratio | 2.62 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.03 | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5
-0.18 (-3.55%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 0.03 | ||
| Fwd PE | N/A | ||
| P/S | 0.15 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.05 | ||
| P/tB | 0.05 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.35% | ||
| ROE | 1.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 5.65% | ||
| GM | 30.41% | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 82.09% | ||
| Cap/Sales | 2.15% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.78 | ||
| Quick Ratio | 2.62 | ||
| Altman-Z | 0.38 |
ChartMill assigns a fundamental rating of 3 / 10 to UPC.
ChartMill assigns a valuation rating of 2 / 10 to UNIVERSE PHARMACEUTICALS INC (UPC). This can be considered as Overvalued.
UNIVERSE PHARMACEUTICALS INC (UPC) has a profitability rating of 3 / 10.
The Price/Earnings (PE) ratio for UNIVERSE PHARMACEUTICALS INC (UPC) is 0.03 and the Price/Book (PB) ratio is 0.05.